We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Sophoricoside ameliorates cardiac hypertrophy by activating AMPK/mTORC1-mediated autophagy.
- Authors
Maomao Gao; Fengjiao Hu; Manli Hu; Yufeng Hu; Hongjie Shi; Guo-Jun Zhao; Chongshu Jian; Yan-Xiao Ji; Xiao-Jing Zhang; Zhi-Gang She; Hongliang Li; Lihua Zhu
- Abstract
Aim: The study aims to evaluate protective effects of sophoricoside (Sop) on cardiac hypertrophy. Meanwhile, the potential and significance of Sop should be broadened and it should be considered as an attractive drug for the treatment of pathological cardiac hypertrophy and heart failure. Methods: Using the phenylephrine (PE)-induced neonatal rat cardiomyocytes (NRCMs) enlargement model, the potent protection of Sop against cardiomyocytes enlargement was evaluated. The function of Sop was validated in mice received transverse aortic coarctation (TAC) or sham surgery. At 1 week after TAC surgery, mice were treated with Sop for the following 4 weeks, the hearts were harvested after echocardiography examination. Results: Our study revealed that Sop significantly mitigated TAC-induced heart dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis. Mechanistically, Sop treatment induced a remarkable activation of AMPK/mTORC1-autophagy cascade following sustained hypertrophic stimulation. Importantly, the protective effect of Sop was largely abolished by the AMPKa inhibitor Compound C, suggesting an AMPK activation-dependent manner of Sop function on suppressing pathological cardiac hypertrophy. Conclusion: Sop ameliorates cardiac hypertrophy by activating AMPK/mTORC1-mediated autophagy. Hence, Sop might be an attractive candidate for the treatment of pathological cardiac hypertrophy and heart failure.
- Publication
Bioscience Reports, 2020, Vol 40, Issue 11, p1
- ISSN
0144-8463
- Publication type
Article
- DOI
10.1042/BSR20200661